The illuminates the intricate decision-making involved in choosing frontline Tyrosine Kinase Inhibitors (TKIs) for individuals with chronic-phase Chronic Myeloid Leukemia (CML). The research highlights the significance of a comprehensive and personalized approach, wherein patient attributes, disease-related aspects, and the safety and effectiveness profiles of TKIs are meticulously evaluated. As the landscape of CML therapy advances, these findings provide invaluable guidance to healthcare professionals in refining treatment approaches, ultimately improving patient results and playing a pivotal role in the continuous advancement of managing this historically burdensome condition.
